A landmark study in 2022 showed that MS risk increased 32-fold among U.S. military recruits who had evidence of prior EBV ...
Repeatedly elevated Epstein-Barr virus antibodies on serial blood tests may help distinguish multiple sclerosis from MOGAD ...
A young mother who travelled overseas for controversial stem cell therapy hopes new treatments will one day be available in ...
By partnering with other like-minded organizations to fund targeted RFAs throughout the year, ACS is able to invest in new ...
Across the Princeton campus and beyond, groundbreaking biomedical advances are emerging from interdisciplinary partnerships ...
Quantum Biopharma has filed with the FDA to start a Phase 2 trial of Lucid-MS to assess the treatment's ability to halt ...
Kristina Callis Duffin, MD, MS, has been named dean of the Spencer Fox Eccles School of Medicine at the University of Utah ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech ...
Hiroshima University researchers have developed a practical framework to identify candidate pathogenic variants hidden among ...
The hospital established a dedicated facility to develop and deploy technology solutions improving clinical operations and ...
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative ...
In the coming weeks, Quantum Biopharma will seek FDA permission for a clinical trial testing Lucid-MS, its therapy to slow myelin loss in MS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results